Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume – Here’s What Happened

Pharming Group (NASDAQ:PHAR) shares saw an uptick in trading volume on Friday . 9,009 shares traded hands during trading, an increase of 51% from the previous session’s volume of 5,954 shares.The stock last traded at $8.40 and had previously closed at $8.86.

Analyst Ratings Changes

Several brokerages recently weighed in on PHAR. HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Tuesday, December 17th. Jefferies Financial Group started coverage on shares of Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price on the stock.

Pharming Group Price Performance

The firm has a market capitalization of $565.34 million, a PE ratio of -31.96 and a beta of -0.10. The company has a 50-day moving average price of $9.21 and a 200-day moving average price of $8.56. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,997 shares of the company’s stock after acquiring an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.